Oncternal Therapeutics, Inc. financial data

Location
12230 El Camino Real, Suite 230, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400 % -57.5%
Debt-to-equity 35.3 %
Return On Equity -178 % -108%
Return On Assets -131 % -73.8%
Operating Margin -1.66K % +75.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.96M shares -95%
Common Stock, Shares, Outstanding 2.96M shares -95%
Entity Public Float 18.8M USD -64.3%
Common Stock, Value, Issued 3K USD -94.9%
Weighted Average Number of Shares Outstanding, Basic 2.96M shares +0.41%
Weighted Average Number of Shares Outstanding, Diluted 2.96M shares +0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.16M USD +228%
General and Administrative Expense 12.3M USD -3.45%
Operating Income (Loss) -36M USD +18.3%
Net Income (Loss) Attributable to Parent -34.6M USD +17.1%
Earnings Per Share, Basic -12 USD/shares +55.9%
Earnings Per Share, Diluted -12 USD/shares +55.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.1M USD -12.4%
Assets, Current 15.4M USD -63.6%
Operating Lease, Right-of-Use Asset 154K USD -47.1%
Other Assets, Noncurrent 0 USD -100%
Assets 15.6M USD -63.9%
Accounts Payable, Current 1.2M USD -43.8%
Employee-related Liabilities, Current 592K USD -52.2%
Accrued Liabilities, Current 5.06M USD +76.6%
Liabilities, Current 6.45M USD +25.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 6.45M USD +4.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -223M USD -18.3%
Stockholders' Equity Attributable to Parent 9.15M USD -75.3%
Liabilities and Equity 15.6M USD -63.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.44M USD +32.2%
Net Cash Provided by (Used in) Financing Activities -87K USD -108%
Net Cash Provided by (Used in) Investing Activities 7.22M USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 2.96M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -301K USD +98.8%
Deferred Tax Assets, Valuation Allowance 66.6M USD +15%
Operating Lease, Liability 191K USD -44.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.6M USD +17.1%
Lessee, Operating Lease, Liability, to be Paid 200K USD -47.1%
Operating Lease, Liability, Current 191K USD +26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 150K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 50K USD -74.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -75%
Deferred Tax Assets, Operating Loss Carryforwards 30M USD +7.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 232M USD +3.01%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 66.6M USD +15%
Share-based Payment Arrangement, Expense 6.81M USD -3.81%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%